89Zr-lintuzumab

N/A

Report date: 2025/11/04 16:07:43

Base Information

Drug Name89Zr-lintuzumab

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-Myeloid cell surface antigen CD33

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc University Of Saskatchewan

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Saskatchewan Actinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A